Affimed (NASDAQ:AFMD) Receives Consensus Recommendation of “Buy” from Analysts

Affimed (NASDAQ:AFMD) has been assigned a consensus rating of “Buy” from the four brokerages that are presently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $20.00.

Several analysts recently issued reports on AFMD shares. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Affimed in a research note on Friday, September 6th.

Affimed Stock Up 0.9 %

Shares of AFMD stock opened at $3.26 on Monday. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. The firm’s 50-day moving average is $3.59 and its two-hundred day moving average is $4.64. Affimed has a 12 month low of $2.92 and a 12 month high of $8.95.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $1.67 million. Equities research analysts anticipate that Affimed will post -4.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Affimed

An institutional investor recently bought a new position in Affimed stock. Choreo LLC acquired a new stake in Affimed (NASDAQ:AFMD) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $54,000. Choreo LLC owned 0.07% of Affimed as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.